GlassScriptPhysician profile
Carlos Schweitzer
NPI 1467548750
$11,876.96
in general payments reported to CMS, 2019-2025
17 companies · $1,235 in 2025
The $1,235 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,530 · 2020: $1,673 · 2021: $1,704 · 2022: $1,405 · 2023: $974 · 2024: $1,355 · 2025: $1,235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,481 · Education: $83.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,480.60 |
| Education | $83.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,114.44 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,532.26 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $1,632.17 | 2019-2023 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $1,488.86 | 2019-2023 | Xarelto |
| Lilly USA, LLC | $1,083.78 | 2019-2025 | Jardiance, Mounjaro |
| Merck Sharp & Dohme LLC | $395.94 | 2019-2020 | |
| Novo Nordisk INC | $358.49 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $323.05 | 2019 | |
| Abbvie INC. | $233.63 | 2021-2024 | Ubrelvy |
| Ardelyx, INC. | $218.56 | 2024-2025 | Ibsrela |
| Amarin Pharma, INC. | $172.08 | 2020-2021 | |
| Pfizer INC. | $162.24 | 2019 | |
| Sunovion Pharmaceuticals INC. | $124.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.32 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.33 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $4.29 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $2.68 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Schweitzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.